AlzeCure Pharma has released new preclinical findings for its lead Alzheimer’s drug candidate, NeuroRestore ACD856, following a presentation at the AD/PD 2026 international conference.

R1 Therapeutics has launched with an oversubscribed $77.5 million Series A financing and an exclusive global licence to ...

Early trial shows more than 50% LRRK2 reduction and supports expansion into other neurodegenerative conditions ...

Incyte has received European Commission approval for Zynyz (retifanlimab) in combination with carboplatin and paclitaxel as a ...

Samsung Bioepis has entered a new global agreement with Sandoz to develop and commercialise up to five next‑generation biosimilar candidates, strengthening a partnership that has been expanding ...

Almirall has reported positive top-line results from its phase 3 ADorable-1 trial, which evaluated lebrikizumab in children ...

Elevara Medicines has dosed the first patient in its phase 2b START-SYNERGY trial, marking a key step in the development of ELV001, an oral CDK4/6 inhibitor being studied for rheumatoid arthritis in ...

Chief Executive Officer Sean A MacDonald added: “The successful completion of this Phase I study represents an important step for Kainova Therapeutics, highlighting the strength of our innovative ...

The MHRA has approved deuruxolitinib, marketed as Leqselvi, for the treatment of severe alopecia areata in adults, offering a new therapeutic option for people living with the autoimmune condition.

Astellas Pharma has announced that the National Institute for Health and Care Excellence has issued Final Draft Guidance recommending fezolinetant 45 mg once daily for treating moderate to severe ...

Atrogi has dosed the first participants in a human study of its lead candidate ATR‑258, marking a significant step forward for the Stockholm-based biotech as it advances its next‑generation approach ...

UCB has announced positive topline results from its BE BOLD trial, the first head‑to‑head study in active psoriatic arthritis to demonstrate superiority of one licensed biologic therapy over an IL‑23 ...